News Regeneron's three-monthly gMG drug Livsayis cleared by FDA Regeneron has joined the crowded gMG market with an siRNA-based therapy, Livsayis, that only needs to be dosed four times a year.
News FDA clears Sanofi's Type 3 Gaucher therapy Infilbray Sanofi's Infilbray has become the first drug to treat neurological symptoms of rare lysosomal storage disorder Type 3 Gaucher disease (GD3) in the US.
News Beren's Niemann-Pick drug Lembaz cleared by FDA The FDA has approved Beren's Lembaz for Niemann-Pick disease type C, the first drug shown to extend survival in the ultra-rare inherited disorder.
News GSK gets second cancer drug approval from Nuvalent buy The FDA has cleared GSK's ALK inhibitor Nelkarmi for a form of lung cancer, the second product from its $10.6bn acquisition of Nuvalent.
News Roche joins the oral SERD club as FDA clears Wilserdly Roche is the latest drugmaker to bring an oral SERD drug for breast cancer to the US market, after getting FDA approval for its Wilserdly product.
News Gazyva is first FDA-cleared drug for rare disease pMN Patients in the US with primary membranous nephropathy have a first approved drug, after the FDA cleared Roche's Gazyva for the rare kidney disorder.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.